Cabot Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cabot Wealth Management's VRTX Position: Q3 2026 in Review
Cabot Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q3 2026, selling an estimated $496K and leaving 930 shares worth $486K. The position accounts for 0.05% of the portfolio, ranked #121.
Cabot Wealth Management first reported a position in VRTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $943K in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Cabot Wealth Management held 930 shares of Vertex Pharmaceuticals worth $486K as of Q3 2026.
- Cabot Wealth Management sold 969 Vertex Pharmaceuticals shares in Q3 2026, an estimated $496K.
- Vertex Pharmaceuticals made up 0.05% of Cabot Wealth Management's portfolio in Q3 2026, its #121 holding.
- Cabot Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
- Cabot Wealth Management's Vertex Pharmaceuticals position peaked at $943K in Q2 2026.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Cabot Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.